Lipocine Inc. (LPCN) — SEC Filings

Latest SEC filings for Lipocine Inc. (LPCN), explained in plain English.

Sentiment Overview: 2 bearish, 48 neutral

Recent Filings (50)

• 8-K Filing — 8-K · 2026-04-02T09:40:13-04:00 [neutral]
• Lipocine Inc. Files 8-K Report — 8-K · 2026-04-02T09:35:13-04:00 [neutral] Risk: low
  On April 2, 2026, Lipocine Inc. filed an 8-K report detailing other events and financial statements. The filing includes exhibits such as the 8-K form itself an
• 8-K Filing — 8-K · 2025-12-16T00:00:00.000Z [neutral]
• Lipocine Inc. Announces Executive and Board Changes — 8-K · 2025-12-15T00:00:00.000Z [neutral] Risk: medium
  Lipocine Inc. announced on December 12, 2025, a series of executive and board changes. Dr. Richard Walovitch has been appointed as Chief Medical Officer, and Dr
• Lipocine Inc. Files 8-K for Financials and Exhibits — 8-K · 2025-12-11T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on December 11, 2025, reporting on events that occurred on December 8, 2025. The filing primarily concerns financial statements and e
• 8-K Filing — 8-K · 2025-11-18T00:00:00.000Z [neutral]
• Lipocine's Q3 Loss Widens Amidst Plummeting License Revenue — 10-Q · 2025-11-06T00:00:00.000Z [bearish] Risk: high
  Lipocine Inc. (LPCN) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $7,257,421, a substantial rise from the
• Lipocine Inc. Files 8-K Report — 8-K · 2025-11-04T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on November 4, 2025, reporting other events and financial statements. The company, formerly known as Marathon Bar Corp until November
• Lipocine Inc. Files 8-K Report — 8-K · 2025-09-30T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K report on September 30, 2025, primarily to disclose other events and financial statements. The filing does not detail specific transa
• Lipocine Inc. Files 8-K — 8-K · 2025-09-26T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on September 26, 2025, reporting on other events and financial statements. The filing does not detail specific transactions or financ
• Lipocine Inc. Files 8-K — 8-K · 2025-09-05T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on September 5, 2025, reporting on other events and financial statements. The filing does not detail specific transactions or financi
• Lipocine Inc. Files 8-K — 8-K · 2025-08-26T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on August 26, 2025, reporting other events and financial statements. The company, previously known as Marathon Bar Corp until Novembe
• Lipocine Narrows Q2 Loss Amidst Zero Revenue — 10-Q · 2025-08-05T00:00:00.000Z [bearish] Risk: high
  Lipocine Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for the three
• Lipocine Inc. Files 8-K Report — 8-K · 2025-07-09T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on July 9, 2025, reporting other events and financial statements. The company, previously known as Marathon Bar Corp until November 3
• Lipocine Inc. Files 8-K Report — 8-K · 2025-07-02T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on July 2, 2025, reporting other events and financial statements. The company, formerly known as Marathon Bar Corp until November 30,
• Lipocine Inc. Files 8-K Report — 8-K · 2025-06-26T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on June 26, 2025, reporting other events and financial statements. The filing does not contain specific details about new material ev
• Lipocine Inc. Files 8-K Report — 8-K · 2025-06-23T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on June 23, 2025, reporting other events and financial statements. The company, previously known as Marathon Bar Corp until November
• Lipocine Inc. Files 8-K — 8-K · 2025-06-09T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on June 9, 2025, reporting other events and financial statements. The company, previously known as Marathon Bar Corp until November 3
• Lipocine Inc. Files 8-K with Corporate Updates — 8-K · 2025-06-04T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on June 4, 2025, reporting on amendments to its articles of incorporation or bylaws, submission of matters to a vote of security hold
• Lipocine Inc. Files 8-K — 8-K · 2025-05-22T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on May 22, 2025, reporting other events and financial statements. The company, previously known as Marathon Bar Corp until November 3
• Lipocine Inc. Files 8-K for Other Events and Exhibits — 8-K · 2025-05-14T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on May 14, 2025, reporting on other events and financial statements. The filing does not detail specific transactions or financial fi
• 8-K Filing — 8-K · 2025-05-12T00:00:00.000Z [neutral]
• Lipocine Inc. Files Q1 2025 10-Q Report — 10-Q · 2025-05-08T00:00:00.000Z [neutral] Risk: medium
  Lipocine Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business operations. Speci
• Lipocine Inc. Files 8-K Report — 8-K · 2025-05-06T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on May 6, 2025, reporting other events and financial statements. The company, previously known as Marathon Bar Corp until November 30
• Lipocine Inc. Files 2024 Executive Compensation Details — DEF 14A · 2025-04-22T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed its DEF 14A on April 22, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes informatio
• 8-K Filing — 8-K · 2025-04-03T00:00:00.000Z [neutral]
• Lipocine Inc. Files 8-K: Procedural Update — 8-K · 2025-03-26T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on March 26, 2025, reporting on other events and financial statements. The filing does not contain specific details about new events,
• Lipocine Inc. Files 2024 Annual Report — 10-K · 2025-03-13T00:00:00.000Z [neutral] Risk: medium
  Lipocine Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting its financial position and business operations. The company, formerly known
• Lipocine Inc. Files 8-K Report — 8-K · 2025-03-12T00:00:00.000Z [neutral] Risk: low
  On March 12, 2025, Lipocine Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates o
• Lipocine Inc. Files 8-K — 8-K · 2025-02-11T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on February 11, 2025, reporting other events and financial statements. The filing does not contain specific details about new events,
• Lipocine Inc. Files 8-K — 8-K · 2025-02-06T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on February 6, 2025, reporting other events and financial statements. The filing does not contain specific details about new material
• Lipocine Inc. Files 8-K Report — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on January 13, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or mater
• Lipocine Inc. Files 8-K: Other Events & Financials — 8-K · 2024-12-17T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on December 17, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not detail specific transacti
• Lipocine Inc. Files 8-K with Office and Contact Details — 8-K · 2024-12-13T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on December 13, 2024, reporting an event. The filing details the company's principal executive offices located at 675 Arapeen Drive,
• Lipocine Inc. Files 8-K: Other Events & Exhibits — 8-K · 2024-11-18T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on November 18, 2024, reporting other events and financial statements. The company, previously known as Marathon Bar Corp until Novem
• Lipocine Inc. Files Q3 2024 10-Q Report — 10-Q · 2024-11-07T00:00:00.000Z [neutral] Risk: medium
  Lipocine Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial performance and operational updates for the th
• Lipocine Inc. Files 8-K for Corporate Updates — 8-K · 2024-11-05T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on November 5, 2024, reporting other events and financial statements. The company, incorporated in Delaware with its principal execut
• Lipocine Inc. Files 8-K — 8-K · 2024-10-31T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on October 31, 2024, reporting an "Other Event" and "Financial Statements and Exhibits" as of October 28, 2024. The filing does not c
• Lipocine Inc. Files 8-K for Material Agreements — 8-K · 2024-10-23T00:00:00.000Z [neutral] Risk: medium
  On October 22, 2024, Lipocine Inc. entered into a material definitive agreement. The company also made modifications to the rights of its security holders and a
• 8-K Filing — 8-K · 2024-10-16T00:00:00.000Z [neutral]
• Lipocine Inc. Files 8-K — 8-K · 2024-10-10T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on October 10, 2024, reporting other events and financial statements. The filing does not contain specific details about new events,
• 8-K Filing — 8-K · 2024-10-08T00:00:00.000Z [neutral]
• Lipocine Inc. Files 8-K — 8-K · 2024-10-02T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on October 2, 2024, reporting other events and financial statements. The company, incorporated in Delaware with its principal executi
• Lipocine Inc. Files 8-K for Other Events and Exhibits — 8-K · 2024-09-30T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on September 30, 2024, reporting other events and financial statements. The filing does not detail specific transactions or material
• Lipocine Inc. Files 8-K for Other Events — 8-K · 2024-09-05T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on September 5, 2024, to report other events and financial statements. The filing does not contain specific details about new events
• Lipocine Inc. Files 8-K — 8-K · 2024-08-27T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on August 27, 2024, reporting other events and financial statements. The filing does not contain specific details on new events, doll
• Lipocine Inc. Files Q2 2024 10-Q — 10-Q · 2024-08-08T00:00:00.000Z [neutral] Risk: medium
  Lipocine Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers financial performance and operational updates for the second quarter of 2024
• Lipocine Inc. Amends Prior Filing on Shareholder Vote Matters — 8-K/A · 2024-08-07T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an amendment (8-K/A) on August 7, 2024, to a previous report originally dated June 5, 2024. This amendment pertains to the submission of mat
• Lipocine Inc. to Acquire Neuro-Bio Ltd. — 8-K · 2024-06-25T00:00:00.000Z [neutral] Risk: medium
  Lipocine Inc. announced on June 25, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of privately held company,
• Lipocine Inc. Files 8-K — 8-K · 2024-06-10T00:00:00.000Z [neutral] Risk: low
  Lipocine Inc. filed an 8-K on June 10, 2024, reporting other events and financial statements/exhibits as of June 8, 2024. The filing does not contain specific d